Axsome settles Auvelity patent litigation with Teva, delaying a generic launch until 2038. Analysts see growth potential with Symbravo's migraine approval.

Neumora Therapeutics Inc. concealed critical issues with its flagship clinical depression drug’s Phase 2 trial, contributing ...

Purpose: The association of antipsychotic and antidepressant drugs with Q-T interval prolongation is reviewed. Summary: Prolongation of the Q-T interval can be of particular concern to ...

A new Cochrane review showed SSRIs and SNRIs outperform placebo for GAD with similar dropout rates, but questions remain ...

SSRIs have been prescribed safely for decades. And this fearmongering from the current administration could have deadly ...

Compared to synthetic drugs, natural plant extracts offer the advantages of being suitable for long-term consumption, having ...

Shares in the brain drug developer rose by more than 20% Monday on news of the deal, which will forestall Teva's generic copy ...

Coalition Senator Jacinta Nampijinpa Price has opened up about her abuse of drugs and alcohol, and what ultimately drove her ...

In people with treatment-resistant depression, investigational inhalable mebufotenin yielded a 15.5-point placebo-adjusted ...

Neurocrine Biosciences Q4 earnings topped forecasts, but revenue slightly missed. Analysts see Ingrezza's long-term growth ...

A coroner concluded in January that Mr Kingston took his own life and was “suffering adverse effects of medication he had ...

SALT LAKE CITY - Lipocine Inc. (NASDAQ: NASDAQ:LPCN), a biopharmaceutical company with a market capitalization of approximately $24 million, announced today that it will conduct a phase 3 safety and ...